Cargando…

Expression and Importance of TMED2 in Multiple Myeloma Cells

OBJECTIVE: TMED2 is a member of the transmembrane emp24 domain (Tmed)/p24 protein family, which is significantly upregulated in breast cancer, ovarian cancer and other tumour tissues. The purpose of this study was to investigate the expression of TMED2 in MM cell lines and its effect on the biologic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ge, Xueling, Jiang, Wei, Jiang, Yujie, Lv, Xiao, Liu, Xin, Wang, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751311/ https://www.ncbi.nlm.nih.gov/pubmed/33364837 http://dx.doi.org/10.2147/CMAR.S278570

Ejemplares similares

The circular RNA CDR1as regulate cell proliferation via TMED2 and TMED10
por: Yang, Xue, et al.
Publicado: (2020)

TMED family genes and their roles in human diseases
por: Zhou, Lv, et al.
Publicado: (2023)

Screening of the novel immune-suppressive biomarkers of TMED family and whether knockdown of TMED2/3/4/9 inhibits cell migration and invasion in breast cancer
por: Fang, Zheng, et al.
Publicado: (2022)

Expression of TMED3 is independently associated with colorectal cancer prognosis
por: Wang, Rong-Fei, et al.
Publicado: (2022)

Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer
por: Lin, Xia, et al.
Publicado: (2019)

TMED2 promotes epithelial ovarian cancer growth
por: Shi-Peng, Gong, et al.
Publicado: (2017)

TMED2/9/10 Serve as Biomarkers for Poor Prognosis in Head and Neck Squamous Carcinoma
por: Gao, Wen, et al.
Publicado: (2022)

Unconventional secretion: cargo channeling by TMED10
por: Nguyen, Tan A., et al.
Publicado: (2020)

TMED2 as a marker of prognosis in breast cancer [Letter]
por: Schwarz, Megan Catherine, et al.
Publicado: (2019)

TMED2 binding restricts SMO to the ER and Golgi compartments
por: Di Minin, Giulio, et al.
Publicado: (2022)

Trafficking protein TMED3 promotes esophageal squamous cell carcinoma
por: Yang, Yuxian, et al.
Publicado: (2023)

Depleting TMED3 alleviates the development of endometrial carcinoma
por: Zhang, Jin, et al.
Publicado: (2022)

TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling
por: Zheng, Hao, et al.
Publicado: (2016)

Knockdown of TMED3 inhibits cell viability and migration and increases apoptosis in human chordoma cells
por: Yang, Jinxing, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease in mice with heterozygous mutation in TMED2
por: Hou, Wenyang, et al.
Publicado: (2017)

The protein secretion modulator TMED9 drives CNIH4/TGFα/GLI signaling opposing TMED3-WNT-TCF to promote colon cancer metastases
por: Mishra, Sonakshi, et al.
Publicado: (2019)

TMED3/RPS15A Axis promotes the development and progression of osteosarcoma
por: Xu, Wei, et al.
Publicado: (2021)

RAB21 interacts with TMED10 and modulates its localization and abundance
por: Del Olmo, Tomas, et al.
Publicado: (2019)

TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR
por: Xie, An, et al.
Publicado: (2021)

Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival
por: Xu, Qinqin, et al.
Publicado: (2016)

TMED10 mediates the trafficking of insulin-like growth factor 2 along the secretory pathway for myoblast differentiation
por: Li, Tiantian, et al.
Publicado: (2023)

TMED3 promotes the development of malignant melanoma by targeting CDCA8 and regulating PI3K/Akt pathway
por: Guo, Xianling, et al.
Publicado: (2023)

PB2268: PAX5 ABERRANT EXPRESSION INCORPORATED IN MIPI-SP RISK SCORING SYSTEM EXHIBITS ADDITIVE VALUE IN MANTLE CELL LYMPHOMA
por: Zhang, Xin, et al.
Publicado: (2023)

TMED3 Promotes Proliferation and Migration in Breast Cancer Cells by Activating Wnt/β-Catenin Signaling
por: Zhang, Xiumei, et al.
Publicado: (2020)

Prognostic Role of TMED3 in Clear Cell Renal Cell Carcinoma: A Retrospective Multi-Cohort Analysis
por: Ha, Mihyang, et al.
Publicado: (2019)

A new type of ERGIC–ERES membrane contact mediated by TMED9 and SEC12 is required for autophagosome biogenesis
por: Li, Shulin, et al.
Publicado: (2021)

Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma
por: Yang, Yi-Chieh, et al.
Publicado: (2021)

TMED3 promotes cell proliferation and motility in breast cancer and is negatively modulated by miR-188-3p
por: Pei, Jing, et al.
Publicado: (2019)

Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer
por: Sial, Nuzhat, et al.
Publicado: (2021)

The many hats of transmembrane emp24 domain protein TMED9 in secretory pathway homeostasis
por: Roberts, Benjamin S., et al.
Publicado: (2023)

The Effects of Promoter Methylation on Downregulation of DAZAP2 in Multiple Myeloma Cell Lines
por: Luo, Sai-Qun, et al.
Publicado: (2012)

Differentially expressed tRFs in CD5 positive relapsed & refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical use
por: Qu, Qingyuan, et al.
Publicado: (2019)

TMED3 Complex Mediates ER Stress‐Associated Secretion of CFTR, Pendrin, and SARS‐CoV‐2 Spike
por: Park, Hak, et al.
Publicado: (2022)

Circular RNA circ_0008305 aggravates hepatocellular carcinoma growth through binding to miR‐186 and inducing TMED2
por: Zhang, Xiaoyu, et al.
Publicado: (2020)

Pim2 is important for regulating DNA damage response in multiple myeloma cells
por: Ramachandran, J, et al.
Publicado: (2016)

The treatment of multiple myeloma--an important MRC trial.
por: Johnson, P. W., et al.
Publicado: (1994)

Asiatic acid, a triterpene, inhibits cell proliferation through regulating the expression of focal adhesion kinase in multiple myeloma cells
por: ZHANG, JUNLI, et al.
Publicado: (2013)

Quantitative Phosphoproteomics of Proteasome Inhibition in Multiple Myeloma Cells
por: Ge, Feng, et al.
Publicado: (2010)

Increased TOX expression associates with exhausted T cells in patients with multiple myeloma
por: Zhao, Yujie, et al.
Publicado: (2022)

IL-17A Increases Multiple Myeloma Cell Viability by Positively Regulating Syk Expression
por: Wang, Shunye, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5b5jb90nqpb3aj3m3jlpqm8s2i